Tumor Budding as an Index to Identify High-Risk Patients with Stage II Colon Cancer

[1]  H. Mitomi,et al.  Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. , 2005, Hepato-gastroenterology.

[2]  H. Mitomi,et al.  Venous invasion and down-regulation of p21(WAF1/CIP1) are associated with metastasis in colorectal carcinomas. , 2005, Hepato-gastroenterology.

[3]  M. Roh,et al.  Intensity of Tumor Budding and Its Prognostic Implications in Invasive Colon Carcinoma , 2005, Diseases of the colon and rectum.

[4]  E. Skrzydlewska,et al.  Activity of cathepsin B and D in colorectal cancer: relationships with tumour budding. , 2004, Anticancer research.

[5]  O. Dent,et al.  Adverse histopathological findings as a guide to patient management after curative resection of node‐positive colonic cancer , 2004, The British journal of surgery.

[6]  Tetsuro Nakamura,et al.  Budding Is Useful to Select High-Risk Patients in Stage II Well-Differentiated or Moderately Differentiated Colon Adenocarcinoma , 2003, Diseases of the colon and rectum.

[7]  K. Hase,et al.  Tumor Budding at the Invasive Margin Can Predict Patients at High Risk of Recurrence After Curative Surgery for Stage II, T3 Colon Cancer , 2003, Diseases of the colon and rectum.

[8]  Y. Atomi,et al.  Coexpression of Matrilysin and Laminin-5 γ2 Chain May Contribute to Tumor Cell Migration in Colorectal Carcinomas , 2003, Digestive Diseases and Sciences.

[9]  M. Oya,et al.  Budding as a useful prognostic marker in pT3 well‐ or moderately‐differentiated rectal adenocarcinoma , 2003, Journal of surgical oncology.

[10]  Y. Atomi,et al.  Laminin-5 γ2 Chain Expression as a Possible Determinant of Tumor Aggressiveness in T1 Colorectal Carcinomas , 2003, Digestive Diseases and Sciences.

[11]  B. Leggett,et al.  APC mutation and tumour budding in colorectal cancer , 2003, Journal of clinical pathology.

[12]  M. Yamaguchi,et al.  Budding (sprouting) as a useful prognostic marker in colorectal mucinous carcinoma. , 2002, Japanese journal of clinical oncology.

[13]  M. Oya,et al.  Budding as a Risk Factor for Lymph Node Metastasis in pT1 or pT2 Well-Differentiated Colorectal Adenocarcinoma , 2002, Diseases of the colon and rectum.

[14]  H. Ueno,et al.  Tumour `budding' as an index to estimate the potential of aggressiveness in rectal cancer , 2002, Histopathology.

[15]  Y. Panis,et al.  Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence , 2001, Diseases of the colon and rectum.

[16]  W. Hohenberger,et al.  High‐risk groups of patients with Stage II colon carcinoma , 2001, Cancer.

[17]  R. Porschen,et al.  Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Fey.  [Adjuvant therapy for colon cancer]. , 2000, Schweizerische medizinische Wochenschrift.

[19]  K. Hase,et al.  Prognostic value of tumor “budding” in patients with colorectal cancer , 1993, Diseases of the colon and rectum.

[20]  M. Morimatsu,et al.  An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer , 1989, Cancer.

[21]  R. Moll,et al.  Tumor dedifferentiation: An important step in tumor invasion , 1985, Clinical & Experimental Metastasis.

[22]  A. Cassoni.  Tnm Classification of Malignant Tumours , 1987 .